Company news
Hinova Pharmaceuticals, Inc. news in 2025
Hinova Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.
Announcement on Resolutions of the 16th Meeting of the 2nd Board of Directors
December 24, 2025
Announcement on Resolutions of the 15th Meeting of the 2nd Board of Directors
December 8, 2025
Announcement on the Voluntary Disclosure of the Inclusion of Deutenzalutamide Soft Capsules in the 2025 National Medical Insurance Drug Catalog
December 7, 2025
Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate Cancer
November 24, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 6, 2025
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Batch of Participants in Phase II Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)
November 4, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
October 30, 2025
Announcement on Resignation of Independent Director and By-election of Independent Director, and Adjustment of Members of Special Committees of the Board of Directors
October 14, 2025
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
September 26, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
Announcement on Result of Shareholding Reduction by Shareholder
September 4, 2025
2025 Semi-annual Report
August 13, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 5%
August 1, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%
July 8, 2025
Announcement on Voluntary Disclosure of Approval of New Drug Marketing Application for Deutenzalutamide Soft Capsules
May 29, 2025
Announcement on Convening the Q1 2025 Performance Briefing
May 26, 2025
Announcement on Share Reduction Plan for Shareholders
May 13, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 9, 2025
Announcement on Application for Mortgage Loan from Bank
April 25, 2025
Announcement on Resolution of the 8th Meeting of the 2nd Board of Supervisors
April 18, 2025
Announcement on Listing and Circulation of Partial Restricted Stocks in Initial Public Offering
April 3, 2025
Announcement on the Expiry of Planned Time for Shareholders with Over 5% Shares to Reduce Shares and Results of Share Reduction
March 25, 2025
Indicative Announcement on Change in Equity of Shareholders Holding More than 5% of Shares
March 5, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Voluntary Disclosure of Completing First Subject Enrollment for Clinical Trial of HP515 Tablets in China
January 19, 2025
Annual Earnings Preannouncement for 2024
January 17, 2025
Announcement on Voluntary Disclosure of Completing First Subject Enrollment for Clinical Trial of Oral PROTAC Drug HP568 Tablets in China
January 9, 2025
Announcement on Extension of Some Investment Projects Financed by Raised Funds from Initial Public Offering of Shares
January 3, 2025